Filing Details
- Accession Number:
- 0001140361-15-035763
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-09-23 17:39:16
- Reporting Period:
- 2015-09-21
- Filing Date:
- 2015-09-23
- Accepted Time:
- 2015-09-23 17:39:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1437402 | Ardelyx Inc. | ARDX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1611311 | P. David Rosenbaum | C/O Ardelyx, Inc. 34175 Ardenwood Blvd, Suite 100 Fremont CA 94555 | Svp, Drug Development | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-09-21 | 800 | $22.09 | 74,252 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2015-09-22 | 600 | $22.00 | 73,652 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 25,880 | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 18, 2015.
- This transaction was executed in multiple trades in prices ranging from $22.00 to $22.37, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The shares are directly held by David Paul Rosenbaum and Susan Edelstein Rosenbaum, Trustees of the David Paul Rosenbaum Family Trust.